Dare Bioscience Files 8-K: Other Events

Ticker: DARE · Form: 8-K · Filed: Jun 25, 2025 · CIK: 1401914

Sentiment: neutral

Topics: 8-k, disclosure

Related Tickers: DBIO

TL;DR

DBIO filed an 8-K for 'Other Events' on 6/25/25. Details TBD.

AI Summary

On June 25, 2025, Dare Bioscience, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific financial transactions or material events were detailed in the provided excerpt.

Why It Matters

This filing signals that Dare Bioscience has reported an event not covered by other standard 8-K items, requiring disclosure to investors.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of 'Other Events' without immediate specific financial or operational impact detailed in the excerpt.

Key Players & Entities

FAQ

What specific event triggered the 'Other Events' disclosure on June 25, 2025?

The provided excerpt does not specify the exact event that triggered the 'Other Events' disclosure.

Is this filing related to a specific product or clinical trial update for Dare Bioscience?

The excerpt does not provide details on whether the 'Other Events' filing is related to a specific product or clinical trial.

What is the significance of the 'Other Events' category in an 8-K filing?

The 'Other Events' category is used for material events that do not fit into the other specific categories of an 8-K report, requiring timely disclosure to the public.

Does this filing indicate any change in Dare Bioscience's executive management or board of directors?

The excerpt does not mention any changes in executive management or board of directors; it only lists 'Other Events'.

What was Dare Bioscience's former company name prior to Tempo Pharmaceuticals Inc?

Dare Bioscience, Inc. was formerly known as Cerulean Pharma Inc. before being Tempo Pharmaceuticals Inc.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 25, 2025 regarding Dare Bioscience, Inc. (DARE).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing